Clinical Trial Update: A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of CMTX-101 in pneumonia was terminated, with no completed safety, tolerability, pharmacokinetics, or immunogenicity results repo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Pneumonia
• Community-acquired Pneumonia

Drugs mentioned

• CMTX-101

Snippet

Sponsor: Clarametyx Biosciences, Inc. | Conditions: Community-acquired Pneumonia, Bacterial Pneumonia | Phase 1 | Status: TERMINATED